Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report)’s share price gapped up prior to trading on Wednesday after the company announced better than expected quarterly earnings. The stock had previously closed at $19.45, but opened at $21.23. Denali Therapeutics shares last traded at $20.2310, with a volume of 975,686 shares traded.
The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.64. The business had revenue of $17.78 million for the quarter, compared to analyst estimates of $12.67 million. During the same quarter last year, the firm posted ($0.74) EPS.
Denali Therapeutics News Roundup
Here are the key news stories impacting Denali Therapeutics this week:
- Positive Sentiment: AVLAYAH generated $17.8 million in net product revenue in its second full commercial quarter. Denali forecast fourth-quarter revenue of $30 million to $32 million, signaling expected acceleration in sales. Denali Q3 2026 results
- Positive Sentiment: BTIG Research reaffirmed its Buy rating and set a $39 price target, substantially above the cited current price of $19.45. BTIG Research ratings
- Positive Sentiment: Denali said its zafinofusp BLA submission remains on track for 2027, and expects data in 2027 from five TransportVehicle programs. These milestones offer potential future catalysts, though they remain subject to development and regulatory risk. Denali Q3 2026 results
- Negative Sentiment: Quarterly net income of $70.1 million included a one-time $194 million gain from selling a Priority Review Voucher, so it may overstate recurring earnings strength. Zacks separately reported a $0.64 per-share loss, narrower than expected and improved from a year earlier. Zacks Q3 earnings report
Analysts Set New Price Targets
DNLI has been the subject of a number of recent analyst reports. BTIG Research reiterated a “buy” rating and issued a $39.00 target price on shares of Denali Therapeutics in a research report on Wednesday. Wedbush boosted their price target on shares of Denali Therapeutics from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Thursday, October 15th. UBS Group upped their price target on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, JPMorgan Chase & Co. began coverage on shares of Denali Therapeutics in a report on Monday, July 13th. They issued an “overweight” rating and a $29.00 price objective for the company. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $35.69.
Read Our Latest Research Report on DNLI
Insider Activity at Denali Therapeutics
In other news, insider Alexander O. Schuth sold 2,768 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $23.44, for a total value of $64,881.92. Following the completion of the sale, the insider owned 278,995 shares in the company, valued at $6,539,642.80. This represents a 0.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.70% of the company’s stock.
Institutional Investors Weigh In On Denali Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in Denali Therapeutics in the 2nd quarter valued at about $360,759,000. ADAR1 Capital Management LLC boosted its position in shares of Denali Therapeutics by 3,490.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock valued at $35,932,000 after purchasing an additional 1,819,339 shares in the last quarter. Bank of America Corp DE acquired a new position in shares of Denali Therapeutics in the 2nd quarter worth approximately $31,660,000. Bank of New York Mellon Corp acquired a new position in shares of Denali Therapeutics in the 2nd quarter worth approximately $20,583,000. Finally, Defilade Capital Management L.P. raised its holdings in shares of Denali Therapeutics by 107.1% in the 1st quarter. Defilade Capital Management L.P. now owns 1,359,969 shares of the company’s stock worth $26,111,000 after purchasing an additional 703,256 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors.
Denali Therapeutics Price Performance
The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. The business’s fifty day moving average is $20.42 and its 200 day moving average is $21.24. The firm has a market capitalization of $3.24 billion, a P/E ratio of -7.13 and a beta of 1.08.
About Denali Therapeutics
Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.
Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.
Featured Stories
- Five stocks we like better than Denali Therapeutics
- High Voltage Returns: Talen Energy Powers the Data Center Rush
- 3 Dividend Increases Above 10%, But Which Offers the Most Income?
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
